PNPLA3 and nonalcoholic fatty liver disease: towards personalized medicine for fatty liver.
作者信息
Yuan Liyun, Terrrault Norah A
机构信息
Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, CA, USA.
出版信息
Hepatobiliary Surg Nutr. 2020 Jun;9(3):353-356. doi: 10.21037/hbsn.2019.10.35.
Abstract
摘要
相似文献
1
PNPLA3 and nonalcoholic fatty liver disease: towards personalized medicine for fatty liver.PNPLA3与非酒精性脂肪性肝病：迈向脂肪肝的个性化医疗
Hepatobiliary Surg Nutr. 2020 Jun;9(3):353-356. doi: 10.21037/hbsn.2019.10.35.
2
PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.非酒精性脂肪性肝病中的PNPLA3 I148M变异：人口统计学和种族特征以及该变异在非酒精性脂肪性肝纤维化中的作用
World J Gastroenterol. 2015 Jan 21;21(3):794-802. doi: 10.3748/wjg.v21.i3.794.
3
PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.PNPLA3基因分型增加了非酒精性脂肪性肝病肥胖患者患非酒精性脂肪性肝炎的易感性。
Surg Obes Relat Dis. 2015 Jul-Aug;11(4):888-94. doi: 10.1016/j.soard.2014.07.016. Epub 2014 Aug 1.
4
PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease.PNPLA3基因rs738409位点是非酒精性脂肪性肝病治疗反应的基础。
World J Clin Cases. 2018 Aug 16;6(8):167-175. doi: 10.12998/wjcc.v6.i8.167.
5
PNPLA3-A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease.PNPLA3——慢性肝病个性化治疗的潜在治疗靶点。
Front Med (Lausanne). 2019 Dec 17;6:304. doi: 10.3389/fmed.2019.00304. eCollection 2019.
6
Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病中循环脂蛋白的遗传决定因素
J Clin Gastroenterol. 2018 May/Jun;52(5):444-451. doi: 10.1097/MCG.0000000000000816.
7
Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic PNPLA3 p.I148M Genetic Variant: An Open-Label Study.携带致脂肪变性 PNPLA3 p.I148M 基因突变的个体中进行为期四周的欧米伽-3 补充：一项开放标签研究。
Lifestyle Genom. 2019;12(1-6):10-17. doi: 10.1159/000502008. Epub 2019 Aug 27.
8
Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease.应对非酒精性脂肪性肝病的药物基因组学和个性化方法。
Pharmacogenomics. 2016 Jul;17(11):1273-1288. doi: 10.2217/pgs-2016-0047. Epub 2016 Jul 5.
9
The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.载脂蛋白基因 PNPLA3 I148M 多态性与血糖正常人群的胰岛素抵抗和非酒精性脂肪性肝病相关。
Liver Int. 2011 Oct;31(9):1326-31. doi: 10.1111/j.1478-3231.2011.02526.x. Epub 2011 Apr 5.
10
PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease.PNPLA3 相关脂肪性肝炎：向基于基因的脂肪性肝病分类迈进。
Semin Liver Dis. 2013 Nov;33(4):369-79. doi: 10.1055/s-0033-1358525. Epub 2013 Nov 12.
引用本文的文献
1
Is UA/HDL-C a Reliable Surrogate Marker for Fatty Liver? A Comparative Evaluation with Metabolic Scores in a Mexican Population: The Genetics of Atherosclerotic Disease Study.尿酸/高密度脂蛋白胆固醇（UA/HDL-C）是脂肪肝的可靠替代标志物吗？墨西哥人群中与代谢评分的比较评估：动脉粥样硬化疾病遗传学研究
Diagnostics (Basel). 2025 Jun 3;15(11):1419. doi: 10.3390/diagnostics15111419.
2
Gene-based therapies for steatotic liver disease.基于基因的脂肪性肝病治疗方法。
Mol Ther. 2025 Jun 4;33(6):2527-2547. doi: 10.1016/j.ymthe.2025.04.024. Epub 2025 Apr 19.
3
Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.通过组学技术解析代谢功能障碍相关脂肪性肝病
Int J Mol Sci. 2025 Feb 13;26(4):1589. doi: 10.3390/ijms26041589.
4
Changes in drinking levels and metabolic dysfunction-associated steatotic liver disease: a longitudinal study from the China multi-ethnic cohort study.饮酒量变化与代谢功能障碍相关脂肪性肝病：来自中国多民族队列研究的纵向研究
BMC Public Health. 2025 Feb 11;25(1):556. doi: 10.1186/s12889-025-21752-1.
5
Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.慢性肝胆疾病的当前治疗方案及有前景的分子疗法
Biomolecules. 2025 Jan 14;15(1):121. doi: 10.3390/biom15010121.
6
The Role of the Liver in the Pathophysiology of PCOS: A Literature Review.肝脏在多囊卵巢综合征病理生理学中的作用：文献综述
Biomolecules. 2025 Jan 2;15(1):51. doi: 10.3390/biom15010051.
7
Epidemiology and outcomes of non-alcoholic fatty liver disease in African Americans.非裔美国人非酒精性脂肪性肝病的流行病学及转归
Clin Liver Dis (Hoboken). 2023 Jun 22;22(3):113-115. doi: 10.1097/CLD.0000000000000064. eCollection 2023 Sep.
8
Exposure to ambient air pollutants, serum miRNA networks, lipid metabolism, and non-alcoholic fatty liver disease in young adults.暴露于环境空气污染物、血清 microRNA 网络、脂质代谢与青年非酒精性脂肪性肝病。
Ecotoxicol Environ Saf. 2023 Oct 1;264:115486. doi: 10.1016/j.ecoenv.2023.115486. Epub 2023 Sep 18.
9
Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort.韩国体检人群中瘦型非酒精性脂肪性肝病的遗传和代谢特征。
Gut Liver. 2024 Mar 15;18(2):316-327. doi: 10.5009/gnl230044. Epub 2023 Aug 10.
10
Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key.非酒精性脂肪性肝病的创新治疗方法：了解您的患者是关键。
Int J Mol Sci. 2023 Jun 27;24(13):10718. doi: 10.3390/ijms241310718.
本文引用的文献
1
Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids.人 PNPLA3-I148M 变异增加多不饱和脂肪酸在肝脏中的蓄积。
JCI Insight. 2019 Aug 22;4(16):127902. doi: 10.1172/jci.insight.127902.
2
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease.载脂蛋白 L3 基因 rs738409C>G 变异与非酒精性脂肪性肝病患者肝脏相关结局的关系。
Clin Gastroenterol Hepatol. 2020 Apr;18(4):935-944.e3. doi: 10.1016/j.cgh.2019.08.011. Epub 2019 Aug 13.
3
Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.用反义寡核苷酸沉默 Pnpla3 可改善 Pnpla3 I148M 敲入小鼠的非酒精性脂肪性肝炎和肝纤维化。
Mol Metab. 2019 Apr;22:49-61. doi: 10.1016/j.molmet.2019.01.013. Epub 2019 Feb 5.
4
Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis.PNPLA3基因rs738409多态性与非酒精性脂肪性肝病（NAFLD）易感性及严重程度的关联：一项荟萃分析。
Medicine (Baltimore). 2019 Feb;98(7):e14324. doi: 10.1097/MD.0000000000014324.
5
New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease.非酒精性脂肪性肝病遗传易感性的新见解及新治疗靶点
Hepatobiliary Surg Nutr. 2018 Oct;7(5):372-381. doi: 10.21037/hbsn.2018.08.05.
6
Genetics and epigenetics of NAFLD and NASH: Clinical impact.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的遗传学和表观遗传学：临床影响。
J Hepatol. 2018 Feb;68(2):268-279. doi: 10.1016/j.jhep.2017.09.003. Epub 2017 Nov 6.
7
Mutant PNPLA3 I148M protein as pharmacological target for liver disease.突变型PNPLA3 I148M蛋白作为肝脏疾病的药理学靶点。
Hepatology. 2017 Oct;66(4):1026-1028. doi: 10.1002/hep.29298. Epub 2017 Aug 26.
8
Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci.肥胖会放大多个基因位点赋予的脂肪肝疾病遗传风险。
Nat Genet. 2017 Jun;49(6):842-847. doi: 10.1038/ng.3855. Epub 2017 Apr 24.
9
Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.热量摄入减少可能会抵消脂肪肝患者中PNPLA3基因p.I148M和TM6SF2基因p.E167K变异的促脂肪变性作用：基于超声的前瞻性研究
Digestion. 2016;93(2):139-48. doi: 10.1159/000441185. Epub 2016 Jan 9.
10
A global reference for human genetic variation.人类遗传变异的全球参考。
Nature. 2015 Oct 1;526(7571):68-74. doi: 10.1038/nature15393.
Zotero 插件